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Methods-A synthetic peptide of the HPV type 16 E7 protein (amino acids 6 to 35) was used to screen sera from 29 children, 130 women with cervical intraepithelial neoplasia, 443 women with cervical cancer, and 222 controls, for antibodies against this viral antigen. Bivariate and multivariate analyses were used to investigate the correlation between the serological status in the pretreatment sera and clinicopathological indices (size of the lesion, histological grade, stromal infiltration, vascular invasion, and nodal spread). Survival analysis was done using the Cox regression model for all FIGO stages and stages IB and IIA. Results-Cervical carcinoma patients had a significantly higher prevalence of antibodies to synthetic peptide E7\6-35 than women with cervical intraepithelial neoplasia (17.7% v 7%, p<O0O5) or controls (17-7% v 11%, p<005) . Bivariate analysis of the data on the presence of anti-E7\6-35 antibodies in the pretreatment sera from these patients and clinicopathological indices showed a significant correlation between the presence of anti-E7\6-35 antibodies and the size of the lesion (p = 0.0009), histological grade (p = 0-031), and lymph node metastasis (p= 0.011). In addition, the Cox regression model, analysing four risk factors which can be determined before treatment, showed a significant correlation between the presence of anti-E7\6-35 antibodies and a worse prognosis (p=0.003). Survival To date, no data have been published concerning the prevalence of antibodies against HPV-16 E7 in sera from patients with cervical squamous cell carcinoma in relation to tumour indices, such as lesion size and nodal spread, or to survival. To investigate the possible correlation between the presence of antibodies against HPV-16 E7 and tumour indices, pretreatment sera from cervical carcinoma patients were tested in an enzyme linked immunosorbent assay (ELISA) using a synthetic peptide. This peptide was chosen to represent reported major B cell epitopes of HPV-16 E7 (aa 2-21,1o aa 1-20 and aa 10-30,7 aa 10-15," aa 10-14,12 and aa .
Using bivariate and logistic regression analysis the results obtained for these cervical cancer patients were correlated with the size of the lesion, histological grade, stromal infiltration, vascular invasion, and nodal spread. In addition, anti-E7 positivity was related to survival.
Methods

SERA
The age distribution of patient and control groups is shown in table 1. Twenty nine sera of children between 0 5 and 9 years of age were used to determine the cut off value. One hundred and thirty sera from women with different grades of cervical intraepithelial neoplasia (CIN) and 51 sera from patients with squamous cell cervical carcinoma were obtained from the Department of Gynaecology, University of Amsterdam Patients with stage IB or IIA were mainly treated by preoperative intracavitary radiotherapy, followed by radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy four weeks later. Postoperative whole pelvis radiotherapy was applied if lymph node metastases or positive resection margins, or both, were present. Patients with stage IIB and most of the patients with stage III were treated by radiotherapy only, ifpossible followed by adjunctive hysterectomy. In the remaining stage III patients and in all stage IV patients, treatment was individualised using combinations of radiotherapy, surgery, and chemotherapy.
To correlate anti-E7 positivity with the histopathological data in bivariate analysis, all the available biopsy or cone material of 300 patients was carefully reviewed. Tumours were classified into well differentiated (grade 1), moderately differentiated (grade 2), poorly differentiated (grade 3 We examined whether tumour associated factors are related to the E7\6-35 serum levels. The results are shown in table 4. Before treatment patients with a lesion size . 4 cm had a significantly higher prevalence of antibodies against E7\6-35 than patients with a lesion size <4 cm (p = 00009). In addition, patients with poorly or undifferentiated carcinoma or with lymph node metastases showed a significantly higher prevalence rate of antibodies against E7\6-35 compared to patients with well or moderately differentiated squamous cell carcinoma (p = 0031) or without lymph node metastases (p=0 011). Finally, for patients with vascular invasion of the tumour a significantly higher prevalence rate of anti-E7\ 6-35 was found in comparison with patients without vascular invasion (p=0 04). In the analysis of clinicopathological data on anti-E7\6-35 using logistic regression analysis we considered stage, lesion size, differentiation grade, and presence or absence of lymph node metastases. The analysis revealed a significant independent effect of both a lesion size . 4 cm and nodal spread on anti-E7\6-35 positivity (X' 17-64; df=2; p=0 0001; sensitivity 33-3%; specificity 90 2%).
We further analysed the predictive value of four pretreatment indices (stage, lesion size, differentiation grade, and anti-E7\6-35 positivity) for the presence of lymph node metastases. Logistic regression analysis showed a statistically significant effect of both anti-E7\ 6-35 positivity and lesion size before treatment on nodal spread (X2= 13-01; df=2; p=0-0015; sensitivity 28-2%; specificity 90 5%).
ANTI-E7\6-35 ANTIBODIES AND PROGNOSIS
When the presence of antibodies against E7\ Anti-E7 positivity was also shown to provide prognostic information. When the prognostic value of anti-E7 positivity was analysed in addition to three prognostic indices which can be determined before therapy (age, lesion size, and histological grade), only anti-E7 positivity correlated with poor survival. The prognostic value of pretreatment anti-E7 positivity may be explained by the association of anti-E7 positivity and tumour spread to the regional lymph nodes, which is a strong indicator of poor prognosis.
In conclusion, the results of this study show that the presence of antibodies against E7\6-35 in pretreatment sera from patients with cervical carcinoma correlates with the size of the lesion, lymph node involvement, and a worse prognosis. However, since anti-E7\6-35 antibodies are only detected in a minority of patients with cervical cancer, the clinical value of detection of antibodies against E7\6-35 as a tumour or progression marker is low. The use of E7 antigens resembling the native state, possibly in combination with E6 antigens, might lead to assays with greater sensitivity and specificity.""1819 The results obtained in this study warrant further studies on the value of antibodies against E7 as tumour or progression markers using E7 antigens resembling the native state.
